And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

As one provider moved from reactive paper-based management to proactive, tech-supported leadership, it has been focused on ...

Discover key insights from Trevi Therapeutics' Q3 2025 earnings call, including clinical progress, strong financials, and upcoming regulatory milestones.

Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics ...

Mangoceuticals, Inc. (NASDAQ: MGRX) ('Mangoceuticals” or the 'Company”) is issuing the following clarification regarding its ...

The company plans to initiate two registrational studies for NDV-01 and a Phase II sepranolone study in the first half of 2026. Traversa also spotlighted the hiring of Dr. Raj Pruthi as Chief Medical ...

KedRAB Supply -- There is a "firm commitment to minimum orders for 2025 through 2027" with distribution agreement extended to ...

Digital transformation sits at the heart of the NHS Long Term Plan, promising a more connected, efficient, and ...

-- 63% complete response (CR) rate at any time (n=62); -- 56% CR rate at 3 months (n=62); -- 62% CR rate at 6 months (n=37), with 4 patients having successfully converted to CR post reinduction; and - ...

P3 Health Partners Inc. (NASDAQ: PIII) Q3 2025 Earnings Call Transcript November 14, 2025 P3 Health Partners Inc. misses on ...

CORONA, CA – November 10, 2025 – PRESSADVANTAGE – Moment of Clarity has published a new resource, “TMS Therapy Success Rate ...

Agentic AI reshaping clinical workflows improves productivity, automates tasks, and enhances governance in health systems, says Dr. Tom Kelly of Heidi.